002294SZSE

Announcement on Abnormal Fluctuations in Stock Trading

✨ AI Summary

Shenzhen Sinovac Pharmaceutical Co., Ltd. announces abnormal stock trading fluctuations due to a cumulative price drop exceeding 20% over three trading days. The company has verified no undisclosed material information, no significant changes in its business operations, and no insider trading. The announcement also highlights the ongoing clinical trial for JK07 (SAL007) for heart failure, noting preliminary but not final results.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Announcement on Abnormal Fluctuations in Stock Trading

The company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and are not aware of any false records, misleading statements, or significant omissions.

I. Introduction to Abnormal Stock Trading Fluctuations

The stock of Shenzhen Sinovac Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") (Stock Abbreviation: Sinovac, Stock Code: 002294) experienced a cumulative price drop deviation exceeding 20% over three consecutive trading days (May 8, 2026, May 11, 2026, and May 12, 2026). In accordance with the relevant regulations of the Shenzhen Stock Exchange, this constitutes abnormal stock trading fluctuations.

II. Company's Attention and Verification of Circumstances

Regarding the abnormal fluctuations in the Company's stock trading, the Company has investigated relevant matters and verified them with its controlling shareholder and actual controller. The relevant circumstances are hereby described as follows:

  1. The information previously disclosed by the Company does not require any correction or supplementation.

  2. The Company has not discovered any undisclosed material information recently reported by public media that may have or has already had a significant impact on the Company's stock trading price.

  3. The Company's current operating condition is sound, and there have been no significant changes in the external market environment, industry policies, or the Company's fundamentals.

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.